EVIDENCE FOR HETEROGENEOUS GROUPS OF NEURONAL DIFFERENTIATION OF EWINGS-SARCOMA

被引:15
作者
HARA, S
ADACHI, Y
KANEKO, Y
FUJIMOTO, J
HATA, J
机构
[1] KEIO UNIV, SCH MED, DEPT PATHOL, 35 SHINANOMACHI, SHINJUKU KU, TOKYO 160, JAPAN
[2] SAITAMA CANC CTR HOSP, DEPT LAB MED, INA, SAITAMA 362, JAPAN
[3] NATL CHILDRENS MED RES CTR, DEPT PATHOL, SETAGAYA KU, TOKYO 154, JAPAN
[4] KEIO UNIV, SCH MED, DEPT SURG, SHINJUKU KU, TOKYO 160, JAPAN
关键词
D O I
10.1038/bjc.1991.458
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated the capability of differentiation of Ewing's sarcoma (ES) towards a neuronal direction through the establishment of four extraosseous ES cell lines and by in vitro stimulation with dibutyryladenosine cyclic monophosphate (db-cAMP) of eight ES lines. All except one of the lines expressed the molecule defined by 5C11, the antibody specifically reactive with ES. Two ES lines expressed a 200 kilodalton (kD) neurofilament protein (NFP) although their original tumours were negative for NFP. Elongation of cytoplasmic processes and increased NFP expression were observed after db-cAMP treatment of these lines and microtubules in the cytoplasmic processes were ultrastructurally demonstrated. Six lines were NFP negative, but three lines changed their morphology after induction of 200 kD NFP expression by db-cAMP treatment. The other three showed no definitive differentiation after db-cAMP treatment. Chromosomal analysis of the new ES lines showed the typical t(11;22) in one line and a +der(22) in two lines. No correlation was observed between the chromosomal abnormality and the differentiation capability. We conclude that ES is a heterogeneous group of tumours with respect to capability of differentiation into the neuronal lineage, but it is clearly distinguished from peripheral primitive neuroectodermal tumours by its 5C11 reactivity.
引用
收藏
页码:1025 / 1030
页数:6
相关论文
共 37 条
[1]   POSTNATAL EXPANSION OF THE NATURAL-KILLER AND KILLER CELL-POPULATION IN HUMANS IDENTIFIED BY THE MONOCLONAL HNK-1 ANTIBODY [J].
ABO, T ;
COOPER, MD ;
BALCH, CM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (01) :321-326
[2]  
ABO T, 1981, J IMMUNOL, V127, P1024
[3]  
ANGERVALL L, 1975, CANCER, V36, P240, DOI 10.1002/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO
[4]  
2-H
[5]  
[Anonymous], 1921, PROC N PATHOL SOC
[6]  
AURIAS A, 1983, NEW ENGL J MED, V309, P496
[7]  
AURIUS A, 1972, NEW ENGL J MED, V32, P906
[8]  
BLOOM ET, 1972, CANCER RES, V32, P906
[9]  
CAVAZZANA AO, 1987, AM J PATHOL, V127, P507
[10]  
DEHNER LP, 1986, ARCH PATHOL LAB MED, V110, P997